Amgen: Excellent Buy And Hold For A Volatile Market
Amgen is a leading biopharmaceutical company that develops innovative medicines in areas with significant unmet needs. Read ...
Amgen Options Trading: A Deep Dive into Market Sentiment
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...
Zacks Investment Research on MSN15d
Amgen Rises Almost 22% YTD: Should You Buy, Hold or Sell the Stock?
Amgen expects key drugs like Repatha, Evenity, Tezspire and oncology and rare disease drugs, as well as biosimilars to drive top-line growth in 2025.Amgen also has some key pipeline assets in obesity ...
pharmaphorum6d
At long last, Amgen/UCB score FDA okay for Evenity
Amgen and UCB finally have FDA approval for osteoporosis drug Evenity, two years after it was turned down by the regulator because of safety concerns. The agency approved Evenity (romosozumab ...
Amgen (NASDAQ:AMGN) Upgraded by StockNews.com to Strong-Buy Rating
Amgen (NASDAQ:AMGN – Get Free Report) was upgraded by research analysts at StockNews.com from a “buy” rating to a “strong-buy ...
Nasdaq27d
Amgen (AMGN) Up 2.9% Since Last Earnings Report: Can It Continue?
Amgen expects key drugs like Repatha, Evenity Tezspire and oncology and rare disease drugs as well as biosimilars to drive top-line growth in 2025. However, the biosimilar erosion of Prolia/Xgeva ...
Quantbot Technologies LP Has $389,000 Stake in Amgen Inc. (NASDAQ:AMGN)
Quantbot Technologies LP boosted its holdings in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 219.5% during the fourth ...
Yahoo Finance27d
Amgen (AMGN) Up 2.9% Since Last Earnings Report: Can It Continue?
Amgen reported fourth-quarter 2024 adjusted ... Ten products, including Repatha, Blincyto, Tezspire, Tavneos and Evenity, achieved double-digit volume growth in the quarter. Rare disease drugs ...